Amgen, Wyeth sued for alleged illegal marketing
Pharma Compliance Alert, March 4, 2009
A whistleblower lawsuit partially unsealed in Massachusetts accuses Amgen of engaging in illegally marketing Aranesp and Enbrel, according to a Wall Street Journal article.
Wyeth, which co-markets Enbrel in the US and Canada, revealed it was also named in the suit in a filing with the SEC.
Read more about the allegations against Amgen and Wyeth.
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- New FAQ posted on storing laryngoscope blades
- Q/A: Coding for telescopic intraocular lens
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Searched
